Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Poster presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2009. New Orleans, LA. [abstract] Blood. 2009 Nov 20; 114(22):2483. doi: 10.1182/blood.V114.22.2483.2483
Candrilli SD, Balkrishnan R, O'Brien SH. Effect of injury severity on the incidence and utilization-related outcomes of venous thromboembolism in pediatric trauma inpatients. Pediatr Crit Care Med. 2009 Sep 1;10(5):554-7.
Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang OH, Rothman KJ. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in non-experimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep 1;54(3):554-60.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.
Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Mateus C, Wolowacz S, Pereira JA. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in total hip and knee replacement in Portugal. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A148.
Earnshaw SR, Jackson DL, Farkouh RA, Schwamm LH. Cost-effectiveness of MRI-based selection of patients for intravenous thrombolysis. Poster presented at the 2009 International Stroke Conference; February 2009. San Diego, CA. [abstract] Stroke. 2009 Apr; 40(4):E192-3.
Leiss JK, Lyden JT, Mathews R, Sitzman KL, Vanderpuije A, Mav D, Kendra MA, Klein C, Humphrey CJ. Blood exposure incidence rates from the North Carolina study of home care and hospice nurses. Am J Ind Med. 2009 Feb 1;52(2):99-104.
Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan 1;101(1):77-85.
Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009 Jan 1;31(1):194-212.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity of patients with hemophilia and inhibitors. Poster presented at the European Conference of the International Society for Pharmacoeconomics and Outcomes Research; November 2008.
Wolowacz SE, Hess N, Brennan VK, Monz BU, Plumb JM. Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years. Curr Med Res Opin. 2008 Oct 1;24(10):2993-3006.
Candrilli S, Balkrishnan R, O'Brien SH. The effect of injury severity on the incidence and resource utilization-related outcomes of deep vein thrombosis among pediatric trauma admissions in the United States. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A246-7.
Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Relative mortality and epoetin alfa dose in hemodialysis patients - Reply. Am J Kidney Dis. 2008 May 1;51(5):865-6.
Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.
Lee WC, Joshi AV, Brown TM, Pashos CL. Patient- and caregiver-reported preferences for characteristics of treatments for hemophilia patients with inhibitors. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada. [abstract] Value Health. 2008 May; 11(3):A164-5.
Pearson IV, Johnson KI. A cost minimization analysis of epoetin zeta for the treatment of anemia associated with chronic kidney disease. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A304.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life of patients with hemophilia and inhibitors. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada. [abstract] Value Health. 2008 May; 11(3):A154.